Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Orlistat-containing pharmaceutical composition for reducing weight

A technology of orlistat and composition, applied in the field of medicine

Active Publication Date: 2017-06-13
ZHONGSHAN WANHAN PHARM CO LTD
View PDF3 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] However, because orlistat mainly acts on the digestive tract, long-term use will cause a series of adverse reactions in the gastrointestinal tract, such as oily spots, flatulence, stool urgency, fatty (oily) diarrhea, steatorrhea, etc. , increased defecation, fecal incontinence, etc., thus limiting the application of this product

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Orlistat-containing pharmaceutical composition for reducing weight
  • Orlistat-containing pharmaceutical composition for reducing weight
  • Orlistat-containing pharmaceutical composition for reducing weight

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Example 1 Preparation of capsules containing orlistat and fructooligosaccharides

[0024] Prescription: (based on 1000 capsules):

[0025]

[0026] Preparation Process:

[0027] Sodium lauryl sulfate, povidone K30, sodium carboxymethyl starch, microcrystalline cellulose, orlistat, and fructooligosaccharide powder were all passed through an 80-mesh sieve before use. Take sodium lauryl sulfate, povidone K30, carboxymethyl starch sodium, microcrystalline cellulose, orlistat, fructooligosaccharide powder of prescription quantity, first a small amount of sodium lauryl sulfate, povidone K30 and carboxymethyl starch sodium were mixed evenly, then added microcrystalline cellulose, orlistat, and fructooligosaccharides, mixed evenly, and passed through an 80-mesh sieve twice. Slowly add 50% ethanol solution containing 10% povidone K30 to the mixed powder to make a soft material, extrude and sieve through a 20-mesh granule, dry the wet granule in a blast drying oven at 30°C f...

Embodiment 2

[0028] Example 2 Preparation of capsules containing orlistat and xylooligosaccharides

[0029] Prescription: (based on 1000 capsules):

[0030]

[0031]

[0032] Preparation Process:

[0033] Sodium lauryl sulfate, povidone K30, sodium carboxymethyl starch, microcrystalline cellulose, orlistat, and xylooligosaccharide powder were all passed through an 80-mesh sieve before use. Weigh the prescribed amount of sodium lauryl sulfate, povidone K30, sodium starch glycolate, microcrystalline cellulose, orlistat, and xylooligosaccharide powder, and first mix a small amount of sodium lauryl sulfate, polyvinyl Mix ketone K30 and carboxymethyl starch sodium evenly, then add microcrystalline cellulose, orlistat, and xylooligosaccharides, mix evenly, and pass through an 80-mesh sieve twice. Slowly add 50% ethanol solution containing 10% povidone K30 to the mixed powder to make a soft material, extrude and sieve through a 20-mesh granule, dry the wet granule in a blast drying oven a...

Embodiment 3

[0034] Example 3 Capsules containing orlistat and soybean oligosaccharides

[0035] Prescription: (based on 1000 capsules):

[0036]

[0037] Preparation Process:

[0038] Sodium lauryl sulfate, povidone K30, sodium starch glycolate, microcrystalline cellulose, orlistat, and soybean oligosaccharide powder are all passed through an 80-mesh sieve before use. Weigh the prescribed amount of sodium lauryl sulfate, povidone K30, sodium starch glycolate, microcrystalline cellulose, orlistat, soybean oligosaccharide powder, first mix a small amount of sodium lauryl sulfate, povidone Mix ketone K30 and carboxymethyl starch sodium evenly, then add microcrystalline cellulose, orlistat, and fructooligosaccharides, mix evenly, and pass through an 80-mesh sieve twice. Slowly add 50% ethanol solution containing 10% povidone K30 to the mixed powder to make a soft material, extrude and sieve through a 20-mesh granule, dry the wet granule in a blast drying oven at 30°C for 6 hours, and tak...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an orlistat-containing pharmaceutical composition for reducing weight. The pharmaceutical composition contains orlistat and oligosaccharide, wherein the weight ratio of the orlistat to the oligosaccharide is 1:(0.1-0.9). The orlistat-containing pharmaceutical composition has the advantages that the weight-reducing effect of the pharmaceutical composition on a rat with nutritional obesity is equivalent to that of the orlistat, and the animal oil discharge degree, caused by the pharmaceutical composition, of an experiment animal is evidently lower than the animal oil discharge degree, caused by the orlistat, of the experiment animal; surprisingly, in-vitro dissolution research results show that the dissolution behavior of the orlistat-containing pharmaceutical composition is better than that of orlistat capsules on the market; the orlistat-containing pharmaceutical composition can keep the weight reducing effect of current orlistat products on the market while the gastrointestinal tract untoward effects caused by the orlistat products can be reduced.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to a pharmaceutical composition containing orlistat for weight loss. Background technique [0002] With the rapid development of social economy and continuous improvement of people's living standards, great changes have taken place in people's diet structure, and the problem of obesity has become more and more serious. Obesity is a metabolic disease caused by the imbalance of the body's energy budget. It is mainly a chronic metabolic disease caused by people's bad eating habits, living habits, and environmental and genetic factors. It is also a disease of hypertension, diabetes, dyslipidemia, coronary heart disease, etc. , myocardial infarction and other risk factors for many diseases, the World Health Organization is rated as the fifth largest risk factor affecting human health. [0003] In recent years, due to people's life pressure, fast pace and lack of health knowledge, the...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/365A61K31/7016A61K31/702A61K31/733A61K31/715A61K9/48A61P3/04
CPCA61K9/4866A61K31/365A61K9/4858A61K47/26A61K47/36A61P1/14A61P3/04
Inventor 向飞杜志博晋春磊徐小林彭韪
Owner ZHONGSHAN WANHAN PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com